Tomoko Ueda-Consolvo1, Noriko Shibuya1, Toshihiko Oiwake1, Shinya Abe1, Ayaka Numata1, Yuuki Honda1, Shuichiro Yanagisawa1, Atsushi Hayashi2. 1. Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. 2. Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. ahayashi@med.u-toyama.ac.jp.
Abstract
PURPOSE: To report the long-term changes of the size of myopic choroidal neovascularization (mCNV) using optical coherence tomography angiography (OCTA). METHODS: This was a retrospective, observational case study of eleven eyes in eleven patients with mCNV followed with OCTA for a minimum of 3 years. The flow area of mCNV on OCTA, the size of chorioretinal atrophy (CRA) and central choroidal thickness were analyzed. The relationship between the changes of mCNV size and recurrences treated with anti-vascular endothelial growth factor (VEGF) agents was also assessed. RESULTS: Three eyes out of eleven eyes showed enlargement of the mCNV over 3 years. In two of the three eyes, the mCNV recurrences had not been treated immediately (the examination intervals were 4 months and 5 months, respectively), and we found obvious enlargement of the mCNV. In three eyes, the mCNV size decreased in 1 year and was stable thereafter without recurrences. In five eyes, mCNV size did not show remarkable changes for 3 years. In three of the five eyes, no recurrences were detected and two of the five eyes underwent prompt treatments against recurrences. CONCLUSION: Regular examination and prompt treatments against recurrences are critical to prevent enlargement of mCNV.
PURPOSE: To report the long-term changes of the size of myopic choroidal neovascularization (mCNV) using optical coherence tomography angiography (OCTA). METHODS: This was a retrospective, observational case study of eleven eyes in eleven patients with mCNV followed with OCTA for a minimum of 3 years. The flow area of mCNV on OCTA, the size of chorioretinal atrophy (CRA) and central choroidal thickness were analyzed. The relationship between the changes of mCNV size and recurrences treated with anti-vascular endothelial growth factor (VEGF) agents was also assessed. RESULTS: Three eyes out of eleven eyes showed enlargement of the mCNV over 3 years. In two of the three eyes, the mCNV recurrences had not been treated immediately (the examination intervals were 4 months and 5 months, respectively), and we found obvious enlargement of the mCNV. In three eyes, the mCNV size decreased in 1 year and was stable thereafter without recurrences. In five eyes, mCNV size did not show remarkable changes for 3 years. In three of the five eyes, no recurrences were detected and two of the five eyes underwent prompt treatments against recurrences. CONCLUSION: Regular examination and prompt treatments against recurrences are critical to prevent enlargement of mCNV.
Authors: Jose M Ruiz-Moreno; Javier A Montero; Javier Araiz; Luis Arias; Alfredo García-Layana; Angela Carneiro; Marta S Figueroa; Rufino Silva Journal: Retina Date: 2015-12 Impact factor: 4.256
Authors: Ji Hwan Lee; Sung Chul Lee; Seo Hee Kim; Hyoung Jun Koh; Sung Soo Kim; Suk Ho Byeon; Christopher Seungkyu Lee Journal: Retina Date: 2017-08 Impact factor: 4.256
Authors: Yong Li; Feihui Zheng; Li Lian Foo; Qiu Ying Wong; Daniel Ting; Quan V Hoang; Rachel Chong; Marcus Ang; Chee Wai Wong Journal: Diagnostics (Basel) Date: 2022-06-08